Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
March 9, 2016
- Japan Generic Market to Reach 1.1 Trillion Yen in 2018: Fuji Keizai
March 9, 2016
- Nemolizumab Shows Efficacy for Atopic Dermatitis in Global PII: Chugai
March 8, 2016
- Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
March 8, 2016
- Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
- Toyama Chemical Sues 3 Generic Firms over Ozex Patent
March 8, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
- Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
March 7, 2016
- Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
- Japan NDA Filed for Anti-HIV Drug Genvoya
March 7, 2016
- NHI Price Reduction Rates for Plavix Generics to Vary Largely between 17.1% and 59.5%: Jiho Tally
March 7, 2016
- Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
March 4, 2016
- Teva Pharma Japan Voluntarily Recalling 7 Products
March 3, 2016
- Public Knowledge-Based Application Filed for Xeloda as Adjuvant Chemotherapy for Rectal Cancer: Chugai
March 3, 2016
- Pfizer Japan Chief Frets Possible Decline in Foreign Investments amid Anti-Innovation Drug Policies
March 3, 2016
- Pfizer’s Japan Sales Tick Up 2% in FY2015
March 3, 2016
- Takeda and Mizuho Medy Tie Up for Marketing of OTC Pregnancy Test Kit, Ovulation Predictor Kit
March 3, 2016
- Eisai Board OKs Hajime Shimizu as 1st President of EA Pharma
March 2, 2016
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
March 1, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…